Wednesday, March 08, 2006

Business World: Biogen Idec, Elan, & Tysabri (Natalizumab) and MS

From the AP, via the New York Times website:

FDA Panel Supports MS Drug's Market Return
Published: March 8, 2006
Filed at 11:24 a.m. ET

WASHINGTON (AP) -- A Food and Drug Administration panel said Wednesday the agency should allow multiple-sclerosis drug Tysabri back on the market.

The drug's manufacturers, Biogen Idec Inc. and Elan Corp., pulled the drug in February 2005 after two patients developed a rare brain disorder, known as progressive multifocal leukoencephalopathy, or PML, and one died. A third patient was later discovered to have PML and also died.

The 12-member panel voted unanimously to support the drug's return.

The FDA usually follows its panel's advice, but isn't required to do so. The agency is expected to make a final decision by the end of the month.
Anthony H. Risser | |

No comments: